<DOC>
	<DOCNO>NCT01556607</DOCNO>
	<brief_summary>The purpose study assess safety tolerability MDT-637 , inhaled subject Intermittent , Mild-to-Moderate Persistent , Asthma .</brief_summary>
	<brief_title>A Trial Assess Safety , Tolerability Pharmacokinetics MDT-637 Subjects With Intermittent , Mild-to-Moderate Persistent , Asthma</brief_title>
	<detailed_description />
	<criteria>1 . Documented clinical history physician diagnosis intermittent mild moderate persistent asthma least 6 month prior screen OR subject historical record Betaagonist reversibility within previous 5 year 2 . Subjects must demonstrate bronchial hyperreactivity methacholine challenge PC20 le 8mg/mL . 3 . Visit 2 FEV1 ( treatment change interim ) must within 12 % Visit 1 result 4 . Males and/or female ( surgically sterile confirm post menopausal ) must agree practice 2 barrier contraception method discharge study 5 . Willing give write informed consent 6 . 18 50 year age 7 . BMI 1930 kg/m2 8 . Nonsmoker ( least 90 day prior screen ) willing abstain smoking course study 9 . Good general health ( except asthma ) determine medical history , physical examination , ECG clinical laboratory test 10 . Willing abstain alcohol , caffeine , xanthinecontaining beverage 24 hour prior dose 24 hour dose . 1 . Uncontrolled , clinically significant disease opinion Principal Investigator , Medical Monitor Sponsor ( MicroDose Therapeutx ; MDTx ) would place subject risk study participation would confound assessment safety MDT637 2 . Inability perform acceptable repeatable spirometry accordance American Thoracic Society/European Respiratory Society ( ATS/ERS ) guideline 3 . Abnormal FEV1 , FVC , FEV1/FVC ( FEV1 FVC &lt; 75 % predict and/or FEV1/FVC ratio &lt; 0.7 ) 4 . FEV1 variability &gt; 12 % Visit 1 Visit 2 5 . Evidence current history additional respiratory disease ( asthma ) ; instance emphysema , chronic bronchitis cystic fibrosis . 6 . Upper respiratory tract infection within 6 week Visit 1 7 . Use rescue albuterol short act bronchodilator ( SAB ) often five time per week 8 . History significant nasal irritation nasal inhalation medication 9 . History malignancy 10 . History clinically significant alcohol drug abuse 11 . Positive drug screen drug abuse 12 . Positive test HIV , Hepatitis B Hepatitis C 13 . Allergy lactose , lactose intolerance 14 . Use prescription medication ( SAB and/or low dose inhale corticosteroid e.g . fluticasone propionate 44 mcg BID budesonide 100 mcg BID equivalent ) within 14 day Visit 2 overthecounter preparation , include dietary herbal supplement , within 5 day Visit 2 15 . Positive urine pregnancy test Visit 1 Visit 2 visit 4 16 . Abnormal QTc interval Visit 1 ( &gt; 450 msec male &gt; 470 msec female ) 17 . Significant blood donation ( test ) previous 8 week 18 . Use Investigational Product previous 6 week ( small molecule product ) previous 3 month ( biologic product )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Respiratory Syncytial Virus Infection</keyword>
	<keyword>RSV</keyword>
</DOC>